Aaron Poh, Kok-Yang Tan, Department of Surgery, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
World J Gastrointest Surg. 2010 Jul 27;2(7):231-41. doi: 10.4240/wjgs.v2.i7.231.
A chronic anal fissure is a common perianal condition. This review aims to evaluate both existing and new therapies in the treatment of chronic fissures. Pharmacological therapies such as glyceryl trinitrate (GTN), Diltiazem ointment and Botulinum toxin provide a relatively non-invasive option, but with higher recurrence rates. Lateral sphincterotomy remains the gold standard for treatment. Anal dilatation has no role in treatment. New therapies include perineal support devices, Gonyautoxin injection, fissurectomy, fissurotomy, sphincterolysis, and flap procedures. Further research is required comparing these new therapies with existing established therapies. This paper recommends initial pharmacological therapy with GTN or Diltiazem ointment with Botulinum toxin as a possible second line pharmacological therapy. Perineal support may offer a new dimension in improving healing rates. Lateral sphincterotomy should be offered if pharmacological therapy fails. New therapies are not suitable as first line treatments, though they can be considered if conventional treatment fails.
慢性肛裂是一种常见的肛周疾病。本综述旨在评估慢性肛裂治疗中现有和新的治疗方法。硝酸甘油(GTN)、地尔硫䓬软膏和肉毒毒素等药物治疗为相对非侵入性的选择,但复发率较高。侧方括约肌切开术仍然是治疗的金标准。肛门扩张在治疗中没有作用。新的治疗方法包括会阴支撑装置、戈那毒素注射、肛裂切除术、肛裂切开术、括约肌松解术和皮瓣手术。需要进一步研究这些新疗法与现有的既定疗法的比较。本文建议初始使用 GTN 或地尔硫䓬软膏加肉毒毒素进行药物治疗,如果药物治疗失败,可考虑使用肉毒毒素作为二线药物。会阴支撑可能为提高愈合率提供新的维度。如果药物治疗失败,应提供侧方括约肌切开术。新的治疗方法不适合作为一线治疗方法,但如果常规治疗失败,可以考虑使用。